Onyx Pharmaceuticals (ONXX) - Bull of the Day

By Zacks.com,  December 05, 2012, 12:00:01 AM EDT

We are upgrading Onyx Pharmaceuticals ( ONXX ) to Outperform based on the company's strong third quarter results and improving prospects. Onyx reported solid third quarter results with revenues increasing 19.3% to $89.5 million, well above the Zacks Consensus Estimate of $81 million.

Third quarter 2012 loss of $0.89 per share was narrower than the Zacks Consensus Estimate of a loss of $1.08. Recently launched Kyprolis is off to a solid start and the strong ramp should continue.

Loss estimates for both 2012 and 2013 have gone down and the Zacks Rank has moved to #2 (short-term Buy rating) from 3 (short-term Hold rating). With two back-to-back product approvals to its credit, Onyx has successfully transformed itself from a one-product company to a multiple-product company.

ONYX PHARMA INC (ONXX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.


This article appears in: Investing, Investing Ideas, Stocks

Referenced Stocks: ONXX



Latest News Video

Residents Clear Up After Taliban Attack
Residents Clear Up After Taliban At...
Jersey Shore Beach Wars
Jersey Shore Beach Wars             
Smirnoff Low-Calorie Vodka: Worth a Sip?
Smirnoff Low-Calorie Vodka: Worth a...


Sign-in
Existing NASDAQ.com member? Log in here.

By signing into to the site using any of the third-party services above, you agree to NASDAQ.com's Terms of Use.

From Our Trusted News Source





Most Active by Volume:

Company Last Sale Change Net / %
BAC $ 13.24 0.03  0.23%
FB $ 24.32 0.74  2.95%
SIRI $ 3.58 0.04  0.99%
GE $ 23.53 0.13  0.55%
PFE $ 29.04 0.07  0.24%
MSFT $ 34.27 0.12  0.35%
INTC $ 23.93 0.12  0.50%
P $ 16.43 0.73  4.25%